Palbociclib (PD0332991) a Selective and Potent Cyclin Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
IMPORTANCE Palbociclib (PD0332991) is a newly developed drug that received breakthrough designation and recent US Food and Drug Administration approval in combination with endocrine therapy in the treatment of hormone receptor positive, ERBB2 negative (formerly HER2 or HER2/neu) breast cancer in the first line metastatic setting. OBJECTIVE Herein we describe the preclinical and translational data and early and late phase clinical trials in which palbociclib has been investigated in a broad array of tumor types. We discuss the pharmacodynamics, pharmacokinetics, toxic effects, and clinical response rates. EVIDENCE REVIEW On March 1, 2015, we conducted a review of the literature describing the development of palbociclib. We used the PubMed search terms "PD0332991," "palbociclib," and "CDK4/6 inhibitor" to find all published articles of interest, without limitation as to publication date. FINDINGS Palbociclib is a potent and specific oral cyclin dependent kinase (CDK) 4/6 inhibitor that has strong preclinical data to support its activity in retinoblastoma protein expressing tumors. Phase 1 trials have demonstrated safety, and phase 2 trials have shown single agent activity in mantle cell lymphoma, breast cancer, liposarcoma, and teratoma with reversible neutropenia as the main toxic effect. Addition of palbociclib to endocrine therapy improves progression free survival in endocrine therapy naive and endocrine therapy resistant metastatic settings. CONCLUSIONS AND RELEVANCE Palbociclib is well tolerated and has therapeutic potential for multiple cancers, including breast cancer, where its efficacy has been demonstrated alone and in combination with endocrine therapy. Additional combinations of palbociclib with endocrine therapy, chemotherapy, and targeted therapy have potential in various tumors, and phase 3 trials are under way.
JAMA oncology